Article
Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.
Haemophilia : the official journal of the World Federation of Hemophilia - 1 Jul 2008
Boekhorst J, Lari G R, D'Oiron R, Costa J M, Nováková I R O, Ala F A, Lavergne J M, VAN Heerde W L
Abstract excerpt
The appearance of inhibitory antibodies against factor VIII (FVIII) is the most severe and costly complication of replacement therapy in patients with haemophilia A (HA). To determine the relationship between FVIII genotype and inhibitor development, baseline FVIII activity, genotype and inhibitor development were reviewed in 1104 patients with HA. In patients with severe HA, splicing errors present the highest...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
